Subscribe
shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
13 February 2020Big PharmaEdward Pearcey

Sanofi wins SCOTUS stay of Lantus patent dispute

Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan over glargine ( Lantus), a treatment for type 2 diabetes.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex
30 January 2020   The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board to more cases.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex
30 January 2020   The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board to more cases.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More on this story

Americas
Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex
30 January 2020   The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board to more cases.
Americas
PTAB institutes IPRs on Sanofi patents
20 December 2017   The US Patent Trial and Appeal Board has instituted inter partes reviews of two patents owned by Sanofi covering Lantus (insulin glargine injection).

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?